ECM
CLDX icon

Element Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Element Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-17,159
Closed -$116K – 682
2018
Q3 		$116K Sell
17,159
-20,697
-55% -$145K ﹤0.01% 836
2018
Q2 		$286K Buy
+37,856
New +$506K 0.01% 565

Other funds holding CLDX

CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Element Capital Management's CLDX Position: Q4 2018 in Review

Element Capital Management sold out of Celldex Therapeutics (CLDX) in Q4 2018, closing a stake of 17,159 shares — an estimated $116K sold.

Element Capital Management first reported a position in CLDX in Q2 2018 and held it in 2 quarters. The position peaked at $286K in Q2 2018. 85 funds tracked by Wall St. Rank hold CLDX as of Q4 2018.

  • Element Capital Management reported no remaining Celldex Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Element Capital Management sold 17,159 Celldex Therapeutics shares in Q4 2018, an estimated $116K.
  • Element Capital Management first reported a position in Celldex Therapeutics in Q2 2018 and held it in 2 quarters.
  • Element Capital Management's Celldex Therapeutics position peaked at $286K in Q2 2018.
  • 85 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2018.

Based on Element Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.